Definitive Contract HHSO100201000045C

This is a federal contract award to Protein Sciences Corp, a for-profit manufacturer, by the National Institute of Allergy and Infectious Diseases (NIAID) within the Department of Health and Human Services (HHS). The $33,250.00 fixed-price level of effort contract is for the procurement of TAS::75 0885::TAS IV P55, 1MG ALIQUOT, CAT # 3005, LOT # 1032-145, with a completion date of June 25, 2010. The contract is not designated as a set-aside. Protein Sciences provides specialized pandemic...

This is a $1,054,186.47 delivery order contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to The Texas A&M University System for the Centers for Innovation in Advanced Development and Manufacturing program. The contract involves technology transfer and cGMP (current Good Manufacturing Practice) manufacture of an adenovirus type 5 (Ad5) vectored anthrax vaccine. No set-aside was used. The prime contractor, Texas A&M...

The Department of Health and Human Services Food and Drug Administration awarded a $17,500 firm fixed price purchase order to Life Technologies Corporation for the purchase of anti-anthrax toxin antibody, raxibacumab, in single glass vials at a concentration of 10 mg/ml. Life Technologies Corporation is a subsidiary of Thermo Electron Corporation Financial Services Division and will deliver the contracted products from its facility in Silver Spring, Maryland by November 27, 2023 to support the...

This is a firm fixed price purchase order contract awarded by the Department of Agriculture's Agricultural Research Service to Proteogenix, a for-profit biotechnology manufacturer, for the custom acquisition of baculoviruses expressing proteins from the African Swine Fever Virus (ASFV). The $240,000 contract was awarded on September 22, 2020 with a completion date of September 29, 2021. The contract did not have a set-aside designation, indicating that it was competed in full and open...

Partner Therapeutics, Inc. was awarded a $748,912 definite contract by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to conduct research and development of diagnostic tests for patients with sepsis and immunoparalysis. The contract was awarded under Special Instructions 019 of the agency's Easy Broad Agency Announcement BAA-20-100-SOL-0002 vehicle. Special Instructions 019 sought host-directed therapeutic candidates to aid long-term...

This federal contract, awarded by the Food and Drug Administration (FDA), provides $2,565,626.00 to the Massachusetts Institute of Technology (MIT) to conduct research and development on "Technologies to Enable Continuous Production of RAAV from SF9/Baculovirus Culture". The contract has no set-aside designation. The work is being performed under the FDA's Broad Agency Announcement for Advanced Regulatory Science, which seeks proposals across eight areas of regulatory science to...

This federal contract award was issued by the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, to Renbio, Inc., a for-profit biotechnology company. The $749,289.42 firm-fixed-price definitive contract, awarded on April 29, 2024, is for research and development on DNA-based delivery of anti-influenza antibodies to large animals under AOI#25 (FASTX) for myo technology. The contract, which has a completion date of February 27, 2026,...

Sanofi Pasteur Inc. was awarded a $59,587.47 firm fixed price delivery order by the Department of Health and Human Services Office of the Assistant Secretary for Administration. The order was issued under the TAS::75 4552 001::TAS contract vehicle for the provision of unspecified vaccine products to be delivered to West Point, Pennsylvania by November 3, 2010. As the prime contractor, Sanofi Pasteur will utilize its manufacturing and distribution capabilities to fulfill agency immunization...

This is a $45,000.00 firm fixed price purchase order contract awarded by the Joint PEO Chemical and Biological Defense, a Defense agency, to Research Corp Technologies Inc. for the renewal of a Pichia license. This license provides the contractor access to proprietary cell bank information and derivative data for use with botulinum toxin vaccine development. The contract has an ultimate completion date of January 30, 2027 and was awarded on July 9, 2024. There was no set-aside used for this...

This firm-fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Proteos Inc., a for-profit organization specializing in the production of recombinant proteins. The $24,248.00 contract is for the expression and purification of OTSA and OTSB proteins in insect cells, with a target of 7.5 mg of OTSA and 2.5 mg of OTSB at a purity greater than 90% and low endotoxin levels. The contract has an...